The Future Of Nano Technology
- Alan Watts
- Anti-Aging Medicine
- David Sinclair
- Gene Medicine
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Hormone Replacement Therapy
- Human Genetic Engineering
- Human Reproduction
- Integrative Medicine
- Life Skills
- Longevity Medicine
- Machine Learning
- Medical School
- Nano Medicine
- Parkinson's disease
- Quantum Computing
- Regenerative Medicine
- Stem Cell Therapy
- Stem Cells
- Medical Coding Specialist Technical Diploma – Northeast …
- Introducing the Anatomage Table Companion App To Visualize Real Human Anatomy with an iPad – PRNewswire
- The anatomy of the Afghan imbroglio: A way forward – Daily Times
- Greys Anatomy Boss Was Excited to Eliminate Shock Death From the Show – Us Weekly
- How It Felt to Give My First Pelvic Exam – Scientific American
|Search Immortality Topics:|
Category Archives: Nano Medicine
Consider the miracle of a pacemaker that promotes heartbeat regularity or an insulin pump that ensures a diabetics pancreatic function both are devices operated by a distant network. Now, imagine if those networks were to fail.Particularly in the age of COVID-19, technology experts are feeling the pressure to develop new strategies to tackle healthcare challenges. Cyber threats in the field of medical technology range from hacking of IoT medical devices, such as insulin pumps and pacemakers, to the PHI of cardiac arrest patients being locked by ransomware attackers, thus preventing timely treatment of patients in critical condition due to heart attack.
While thousands of patients utilize such medical devices, the security of these systems lies with the networks remotely powering the device. Moreover, nanomedicine or the use of nantotechnology for healthcare purposes such as eradication of cancer cells also relies on such distant networks. Like any computer network, SCADA systems face risks from a variety of cyber-attacks.
Recently, Dr. Gregory Carpenter, a Cyber Epidemiologist at KnowledgeBridge International Inc., has revealed his teams investigation results, including the discovery that 23 of the 25 bio-nano carrier networks tested were vulnerable to basic DDoS attacks, as well as other legacy threats such as outdated and unpatched systems exposed to zero-day attacks.
The operational nature of SCADA especially in healthcare remains highly collaborative, with medical staff sharing data amongst themselves as well as hospital IT teams sharing information with cloud brokers and providers. Indeed, as more medical organizations migrate to the cloud, such data sharing coupled with the lack of visibility inherent to the cloud environment poses many risks.
As the attack surface increases l with both medical IoT and PHIs exposure to the cloud, hospitals and medical device providers could benefit from ensuring that patient information is encrypted and their cloud providers have secure defenses in place against denial of service attacks.
In the area of cloud security, healthcare organizations should e bear in mind that while their cloud service providers control the physical security of the servers in their data centers, as cloud customers, the organizations themselves hold responsibility for encrypting data in transit. Therefore, all data whether PHI or related to the operations of medical technology should remain top priority for in-transit security.
In-transit encryption best practices involve the key elements of defining data protection requirements, implementing secure certificate and stored key management, automating data leak detection and authenticating network communications via IPSec or TLS protocols. Such steps to enforcement will help assure that data moving between the cloud provider and healthcare entity endpoint remains secure.
A helpful starting point might entail configuring load balancers to only interact with HTTPS traffic in order to promote encrypted movement of data between the host organization and cloud service provider. Another solution to in-transit security lies in the use of VPN between the cloud provider and healthcare customer. Additionally, both provider and customer must maintain cognizance surrounding faults in availability, in terms of impact to quality of care as well as implications regarding the potential underlying context of such events.
In particular, phishing campaigns have often worked in parallel to larger-scale attacks such as DDoS, in an attempt to infiltrate the target network while security teams focus on the availability-based incident. Therefore, healthcare senior management and IT personnel who observe compromise attempts via network intrusion detection data can help safeguard against a breach by warning all employees to remain vigilant regarding potential phishing emails.
As email-based attacks have especially targeted the healthcare industry amidst the recent COVID-19 crisis, medical professionals and their patients stand to gain the most from hospital management and practitioners learning how to avoid such correlated threats.
To this effect, security awareness training provides an optimal defense against the possibility for data compromise by human error. With fewer physicians and hospital administrators falling victim to scareware and other malicious email-based activity, the attack vector shrinks for cyber-criminals looking to capitalize on the panic over the current global pandemic.
Furthermore, network administrators in the healthcare space can do their part by tightly monitoring infrastructure for any penetration attempt. A place to begin might be examining signs of botnet activity and other availability-based attacks with phishing attempts that occur within a similar timeframe of around 24 hours or fewer. As soon as a security team detects a compromise, all associated medical devices must be immediately remotely deactivated.
Perhaps most importantly, providers of biotechnology as well as hospital services must maintain transparency with all customers and patients regarding any suspected or successful breaches. After all, the individuals receiving treatment in these instances face the highest risk, as any successful attacker holds the power to not only access PHI, but potentially also to hack into a medical device on which a human life might depend.
Sarah Katz is an author working in information security at NASA. Since graduating from UC Berkeley, she has published various pieces in research and science fiction, primarily surrounding the intersection of medicine and technology. Most recently, she has founded Cysec Health, a nonprofit group of cybersecurity volunteers supporting women's health organizations amid the COVID-19 pandemic.
View original post here:
Securing Medical Technology in the Age of COVID-19 - Infosecurity Magazine
Nanobots Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026| Xidex Corp, Zymergen Inc, Synthace Limited, Ginkgo…
LOS ANGELES, United States:QY Research has recently published a report, titled Global Nanobots Market Research Report 2020-2026.The research report provides an in-depth explanation of the various factors that are likely to drive the market. It discusses the future of the market by studying the historical details. Analysts have studied the ever-changing market dynamics to evaluate their impact on the overall market. In addition, the Nanobots report also discusses the segments present in the market. Primary and secondary research methodologies have been used to provide the readers with an accurate and precise understanding of the overall Nanobots market. Analysts have also given readers an unbiased opinion about the direction companies will take during the forecast period.
The research report also includes the global Nanobots market figures that provide historical data as well as estimated figures. It gives a clear picture of the growth rate of the market during the forecast period. The Nanobots report aims to give the readers quantifiable data that is collected from verified data. The report attempts to answer all the difficult questions such as market sizes and company strategies.
Download Full PDF Sample Copy ofNanobots Report with TOC, figure and tables: https://www.qyresearch.com/sample-form/form/1738855/impact-of-covid-19-outbreak-on-nanobots-global-and-japan-market
The vendor landscape and competitive scenarios of the global Nanobots market are broadly analyzed to help market players gain competitive advantage over their competitors. Readers are provided with detailed analysis of important competitive trends of the global Nanobots market. Market players can use the analysis to prepare themselves for any future challenges well in advance. They will also be able to identify opportunities to attain a position of strength in the global Nanobots market. Furthermore, the analysis will help them to effectively channelize their strategies, strengths, and resources to gain maximum advantage in the global Nanobots market.
Key Players Mentioned in the Global Nanobots Market Research Report: Xidex Corp, Zymergen Inc, Synthace Limited, Ginkgo Bioworks, Advanced Diamond Technologies, Advanced Nano Products Co Limited
Global Nanobots Market Segmentation by Product: Microbivore Nanorobots, Respirocyte Nanorobots, Clottocyte Nanorobots, Cellular Repair Nanorobots
Global Nanobots Market Segmentation by Application: Nano Medicine, Biomedical, Mechanical, Other applications
The report comes out as an accurate and highly detailed resource for gaining significant insights into the growth of different product and application segments of the global Nanobots market. Each segment covered in the report is exhaustively researched about on the basis of market share, growth potential, drivers, and other crucial factors. The segmental analysis provided in the report will help market players to know when and where to invest in the global Nanobots market. Moreover, it will help them to identify key growth pockets of the global Nanobots market.
Key Questions Answered
Request for customization in Report:https://www.qyresearch.com/customize-request/form/1738855/impact-of-covid-19-outbreak-on-nanobots-global-and-japan-market
Table of Content
1 Study Coverage1.1 Nanobots Product Introduction1.2 Market Segments1.3 Key Nanobots Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global Nanobots Market Size Growth Rate by Type1.4.2 Microbivore Nanorobots1.4.3 Respirocyte Nanorobots1.4.4 Clottocyte Nanorobots1.4.5 Cellular Repair Nanorobots1.5 Market by Application1.5.1 Global Nanobots Market Size Growth Rate by Application1.5.2 Nano Medicine1.5.3 Biomedical1.5.4 Mechanical1.5.5 Other applications1.6 Coronavirus Disease 2019 (Covid-19): Nanobots Industry Impact1.6.1 How the Covid-19 is Affecting the Nanobots Industry188.8.131.52 Nanobots Business Impact Assessment Covid-184.108.40.206 Supply Chain Challenges220.127.116.11 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Nanobots Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-18.104.22.168 Government Measures to Combat Covid-19 Impact22.214.171.124 Proposal for Nanobots Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered
2 Executive Summary2.1 Global Nanobots Market Size Estimates and Forecasts2.1.1 Global Nanobots Revenue 2015-20262.1.2 Global Nanobots Sales 2015-20262.2 Nanobots Market Size by Region: 2020 Versus 20262.3 Nanobots Historical Market Size by Region (2021-2026)2.3.1 Global Nanobots Retrospective Market Scenario in Sales by Region: 2015-20202.3.2 Global Nanobots Retrospective Market Scenario in Revenue by Region: 2015-20202.4 Nanobots Market Estimates and Projections by Region (2021-2026)2.4.1 Global Nanobots Sales Forecast by Region (2021-2026)2.4.2 Global Nanobots Revenue Forecast by Region (2021-2026)
3 Global Nanobots Competitor Landscape by Players3.1 Global Top Nanobots Sales by Manufacturers3.1.1 Global Nanobots Sales by Manufacturers (2015-2020)3.1.2 Global Nanobots Sales Market Share by Manufacturers (2015-2020)3.2 Global Nanobots Manufacturers by Revenue3.2.1 Global Nanobots Revenue by Manufacturers (2015-2020)3.2.2 Global Nanobots Revenue Share by Manufacturers (2015-2020)3.2.3 Global Nanobots Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Nanobots Revenue in 20193.2.5 Global Nanobots Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Global Nanobots Price by Manufacturers3.4 Global Nanobots Manufacturing Base Distribution, Product Types3.4.1 Nanobots Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Nanobots Product Type3.4.3 Date of International Manufacturers Enter into Nanobots Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)4.1 Global Nanobots Market Size by Type (2015-2020)4.1.1 Global Nanobots Sales by Type (2015-2020)4.1.2 Global Nanobots Revenue by Type (2015-2020)4.1.3 Nanobots Average Selling Price (ASP) by Type (2015-2026)4.2 Global Nanobots Market Size Forecast by Type (2021-2026)4.2.1 Global Nanobots Sales Forecast by Type (2021-2026)4.2.2 Global Nanobots Revenue Forecast by Type (2021-2026)4.2.3 Nanobots Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Nanobots Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Breakdown Data by Application (2015-2026)5.1 Global Nanobots Market Size by Application (2015-2020)5.1.1 Global Nanobots Sales by Application (2015-2020)5.1.2 Global Nanobots Revenue by Application (2015-2020)5.1.3 Nanobots Price by Application (2015-2020)5.2 Nanobots Market Size Forecast by Application (2021-2026)5.2.1 Global Nanobots Sales Forecast by Application (2021-2026)5.2.2 Global Nanobots Revenue Forecast by Application (2021-2026)5.2.3 Global Nanobots Price Forecast by Application (2021-2026)
6 China by Players, Type and Application6.1 China Nanobots Market Size YoY Growth 2015-20266.1.1 China Nanobots Sales YoY Growth 2015-20266.1.2 China Nanobots Revenue YoY Growth 2015-20266.1.3 China Nanobots Market Share in Global Market 2015-20266.2 China Nanobots Market Size by Players (International and Local Players)6.2.1 China Top Nanobots Players by Sales (2015-2020)6.2.2 China Top Nanobots Players by Revenue (2015-2020)6.3 China Nanobots Historic Market Review by Type (2015-2020)6.3.1 China Nanobots Sales Market Share by Type (2015-2020)6.3.2 China Nanobots Revenue Market Share by Type (2015-2020)6.3.3 China Nanobots Price by Type (2015-2020)6.4 China Nanobots Market Estimates and Forecasts by Type (2021-2026)6.4.1 China Nanobots Sales Forecast by Type (2021-2026)6.4.2 China Nanobots Revenue Forecast by Type (2021-2026)6.4.3 China Nanobots Price Forecast by Type (2021-2026)6.5 China Nanobots Historic Market Review by Application (2015-2020)6.5.1 China Nanobots Sales Market Share by Application (2015-2020)6.5.2 China Nanobots Revenue Market Share by Application (2015-2020)6.5.3 China Nanobots Price by Application (2015-2020)6.6 China Nanobots Market Estimates and Forecasts by Application (2021-2026)6.6.1 China Nanobots Sales Forecast by Application (2021-2026)6.6.2 China Nanobots Revenue Forecast by Application (2021-2026)6.6.3 China Nanobots Price Forecast by Application (2021-2026)
7 North America7.1 North America Nanobots Market Size YoY Growth 2015-20267.2 North America Nanobots Market Facts & Figures by Country7.2.1 North America Nanobots Sales by Country (2015-2020)7.2.2 North America Nanobots Revenue by Country (2015-2020)7.2.3 U.S.7.2.4 Canada
8 Europe8.1 Europe Nanobots Market Size YoY Growth 2015-20268.2 Europe Nanobots Market Facts & Figures by Country8.2.1 Europe Nanobots Sales by Country8.2.2 Europe Nanobots Revenue by Country8.2.3 Germany8.2.4 France8.2.5 U.K.8.2.6 Italy8.2.7 Russia
9 Asia Pacific9.1 Asia Pacific Nanobots Market Size YoY Growth 2015-20269.2 Asia Pacific Nanobots Market Facts & Figures by Country9.2.1 Asia Pacific Nanobots Sales by Region (2015-2020)9.2.2 Asia Pacific Nanobots Revenue by Region9.2.3 China9.2.4 Japan9.2.5 South Korea9.2.6 India9.2.7 Australia9.2.8 Taiwan9.2.9 Indonesia9.2.10 Thailand9.2.11 Malaysia9.2.12 Philippines9.2.13 Vietnam
10 Latin America10.1 Latin America Nanobots Market Size YoY Growth 2015-202610.2 Latin America Nanobots Market Facts & Figures by Country10.2.1 Latin America Nanobots Sales by Country10.2.2 Latin America Nanobots Revenue by Country10.2.3 Mexico10.2.4 Brazil10.2.5 Argentina
11 Middle East and Africa11.1 Middle East and Africa Nanobots Market Size YoY Growth 2015-202611.2 Middle East and Africa Nanobots Market Facts & Figures by Country11.2.1 Middle East and Africa Nanobots Sales by Country11.2.2 Middle East and Africa Nanobots Revenue by Country11.2.3 Turkey11.2.4 Saudi Arabia11.2.5 U.A.E
12 Company Profiles12.1 Xidex Corp12.1.1 Xidex Corp Corporation Information12.1.2 Xidex Corp Description, Business Overview and Total Revenue12.1.3 Xidex Corp Sales, Revenue and Gross Margin (2015-2020)12.1.4 Xidex Corp Nanobots Products Offered12.1.5 Xidex Corp Recent Development12.2 Zymergen Inc12.2.1 Zymergen Inc Corporation Information12.2.2 Zymergen Inc Description, Business Overview and Total Revenue12.2.3 Zymergen Inc Sales, Revenue and Gross Margin (2015-2020)12.2.4 Zymergen Inc Nanobots Products Offered12.2.5 Zymergen Inc Recent Development12.3 Synthace Limited12.3.1 Synthace Limited Corporation Information12.3.2 Synthace Limited Description, Business Overview and Total Revenue12.3.3 Synthace Limited Sales, Revenue and Gross Margin (2015-2020)12.3.4 Synthace Limited Nanobots Products Offered12.3.5 Synthace Limited Recent Development12.4 Ginkgo Bioworks12.4.1 Ginkgo Bioworks Corporation Information12.4.2 Ginkgo Bioworks Description, Business Overview and Total Revenue12.4.3 Ginkgo Bioworks Sales, Revenue and Gross Margin (2015-2020)12.4.4 Ginkgo Bioworks Nanobots Products Offered12.4.5 Ginkgo Bioworks Recent Development12.5 Advanced Diamond Technologies12.5.1 Advanced Diamond Technologies Corporation Information12.5.2 Advanced Diamond Technologies Description, Business Overview and Total Revenue12.5.3 Advanced Diamond Technologies Sales, Revenue and Gross Margin (2015-2020)12.5.4 Advanced Diamond Technologies Nanobots Products Offered12.5.5 Advanced Diamond Technologies Recent Development12.6 Advanced Nano Products Co Limited12.6.1 Advanced Nano Products Co Limited Corporation Information12.6.2 Advanced Nano Products Co Limited Description, Business Overview and Total Revenue12.6.3 Advanced Nano Products Co Limited Sales, Revenue and Gross Margin (2015-2020)12.6.4 Advanced Nano Products Co Limited Nanobots Products Offered12.6.5 Advanced Nano Products Co Limited Recent Development12.11 Xidex Corp12.11.1 Xidex Corp Corporation Information12.11.2 Xidex Corp Description, Business Overview and Total Revenue12.11.3 Xidex Corp Sales, Revenue and Gross Margin (2015-2020)12.11.4 Xidex Corp Nanobots Products Offered12.11.5 Xidex Corp Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Nanobots Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 Nanobots Customers14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source16.2 Author Details
We established as a research firm in 2007 and have since grown into a trusted brand amongst many industries. Over the years, we have consistently worked toward delivering high-quality customized solutions for wide range of clients ranging from ICT to healthcare industries. With over 50,000 satisfied clients, spread over 80 countries, we have sincerely strived to deliver the best analytics through exhaustive research methodologies.
Global Healthcare Nanotechnology Market :Growth and Changes Influencing the Industry 2020-2026 – News Distinct
The research report on Healthcare Nanotechnology Market provides comprehensive analysis on market status and development pattern, including types, applications, rising technology and region. Healthcare Nanotechnology Market report covers the present and past market scenarios, market development patterns, and is likely to proceed with a continuing development over the forecast period. The report covers all information on the global and regional markets including historic and future trends for market demand, size, trading, supply, competitors, and prices as well as global predominant vendors information.
The Outlook Of Global Healthcare Nanotechnology Market:
AmgenTeva PharmaceuticalsAbbottUCBRocheCelgeneSanofiMerck & CoBiogenStrykerGilead SciencesPfizer3M CompanyJohnson & JohnsonSmith & NephewLeadiant BiosciencesKyowa Hakko KirinShireIpsenEndo International
This market research report on the Healthcare Nanotechnology Market is an all-inclusive study of the business sectors up-to-date outlines, industry enhancement drivers, and manacles. It provides market projections for the coming years. It contains an analysis of late augmentations in innovation, Porters five force model analysis and progressive profiles of hand-picked industry competitors. The report additionally formulates a survey of minor and full-scale factors charging for the new applicants in the market and the ones as of now in the market along with a systematic value chain exploration.
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Types Of Global Healthcare Nanotechnology Market:
NanomedicineNano Medical DevicesNano DiagnosisOther
Applications Of Global Healthcare Nanotechnology Market:
Get Upto 40% discount on this [emailprotected]:https://www.globalmarketers.biz/discount_inquiry/discount/130533
The competitive landscape of the Healthcare Nanotechnology Market is discussed in the report, including the market share and new orders market share by company. The report profiles some of the leading players in the global market for the purpose of an in-depth study of the challenges faced by the industry as well as the growth opportunities in the market. The report also discusses the strategies implemented by the key companies to maintain their hold on the industry. The business overview and financial overview of each of the companies have been analyzed.
This report provide wide-ranging analysis of the impact of these advancements on the markets future growth, wide-ranging analysis of these extensions on the markets future growth. The research report studies the market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period.
Key questions answered in this research report:
What will the market size in the forecast period?
What are the recent trends which are influencing the growth of Healthcare Nanotechnology Market?
What are the outcomes of SWOT analysis?
What are the global opportunities for expanding the Healthcare Nanotechnology Market?
Who are the key players, vendors, and sellers of Healthcare Nanotechnology Market?
What are the influencing factors of the global market?
Table of Contents:
Global Healthcare Nanotechnology Market Research Report
Chapter 1-Healthcare Nanotechnology Market Overview
Chapter 2 Global Economic Impact on Industry
Chapter 3 Global Market Competition by Manufacturers
Chapter 4 Global Production, Revenue (Value) by Region
Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions
Chapter 6 Global Production, Revenue (Value), Price Trend by Type
Chapter 7 Global Market Analysis by Application
Chapter 8 Manufacturing Cost Analysis
.CONTINUED FOR TOC
Get Full Table of content @ https://www.globalmarketers.biz/report/medicine/global-healthcare-nanotechnology-market-2019-by-company,-regions,-type-and-application,-forecast-to-2024/130533#table_of_contents
If you have any special requirements, please let us know and we will offer you the report as you want.
Nanobiotix Announces Positive First Results From Phase I Expansion in Locally Advanced Head and Neck Cancer at ASCO 2020 – Press Release – Digital…
PARIS & CAMBRIDGE, Mass.--(Business Wire)--Regulatory News:
NANOBIOTIX (Paris:NANO)(Euronext: NANO - ISIN: FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced new data from the expansion part of its phase I trial, evaluating the potential of first-in-class NBTXR3 activated by radiation therapy to improve treatment outcomes for elderly patients with locally advanced head and neck cancer ineligible for chemotherapy or intolerant to cetuximab. The data were published as part of the virtual scientific program at the 2020 annual meeting of the American Society for Clinical Oncology (ASCO).
Study 102: A phase I trial of hafnium oxide nanoparticles activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients
Authors: Christophe Le Tourneau, Valentin Calugaru, Edith Borcoman, Victor Moreno, Emiliano Calvo, Xavier Liem, Sebastien Salas, Bernard Doger, Olivier Choussy, Maria Lesnik, Xavier Mirabel, Nathalie Badois, Samar Krhili, Josefin Blomkvist, Nicolas Fakhry, Stphanie Wong-Hee-Kam, Caroline Hoffmann.
J Clin Oncol 38: 2020 (suppl; abstr 6573). DOI: 10.1200/JCO.2020.38.15_suppl.6573.
Abstract Number: 6573
After reporting promising early signs of activity from the dose escalation part of its phase I trial evaluating the safety and feasibility of NBTXR3 activated by radiation therapy in elderly patients with locally advanced head and neck squamous cell carcinoma (HNSCC), the Company launched an expansion cohort to confirm results and observed trends with a larger population treated at the recommended dose. This part of the study is expected to recruit a total of 44 evaluable patients. To date, 40 patients have been recruited, 30 of whom are evaluable for efficacy and are included in the data presented at ASCO 2020.
As previously announced, in the dose escalation part of the study NBTXR3 activated by radiation therapy was safe and well tolerated. The recommended phase 2 dose (RP2D) was determined to be 22% of baseline tumor volume. Among 16 evaluable patients, injected lesion complete response rate was 56% and overall objective response rate was 69%.
Regarding the new, expansion part data, analysis of 40 patients dosed showed that NBTXR3 activated by radiation therapy remains safe and well tolerated. In terms of efficacy, for the 30 evaluable patients, investigators observed, at a median time of 5 months after NBTXR3 injection, an overall objective response rate of 83% and an overall complete response rate of 43% and objective response rate of the primary tumor (target lesion) of 83% with a complete response rate of the primary tumor of 60%. The safety profile was consistent with the dose escalation part and the efficacy data improved (i.e. an increase in overall objective response rate from 69% in the dose escalation part to 83% in the dose expansion part).
In the safety population (all treated patients, N=40), three serious adverse events (SAEs) related to NBTXR3 were observed (0.7% of all AEs), comprising one case each of: Grade 4 tumor hemorrhage also related to radiotherapy, Grade 3 mucosal inflammation and Grade 2 swollen tongue also related to the injection procedure. Two SAEs related to the injection procedure were reported (0.5% of all AEs), comprising: two cases of swollen tongue, of which one was Grade 2 and also related to NBTXR3, and one was Grade 4. The radiotherapy-associated safety profile was as expected with the most frequently occurring AEs being stomatitis and skin injury. Three deaths due to AEs related to radiotherapy and other causes were observed. Four other patients died of non-oncologic or non-toxicity-related reasons.
Next Steps in Head and Neck Cancer
The expansion part of the phase I trial will continue to recruit until reaching 44 evaluable patients. In parallel, subject to the FDAs pending review, the Company intends to globally launch a pivotal phase III trial. In the planned phase III trial, a futility analysis is expected 18 months after the first patient is randomized, and an interim analysis of progression-free survival (PFS) is expected at 24-30 months.
NBTXR3 for the treatment of locally advanced HNSCC patients who are not eligible for platinum-based chemotherapy received Fast Track designation from the FDA in February 2020. Fast Track designation is a process designed to facilitate the development and accelerate the review of drugs for serious conditions that have the potential to address unmet medical needs. The purpose is to expedite the availability of new treatment options for patients.
NBTXR3 is a first-in-class product designed to destroy tumors through physical cell death when activated by radiotherapy. NBTXR3 has a high degree of biocompatibility, requires one single administration before the first radiotherapy treatment session, and has the ability to fit into current worldwide radiation therapy standards of care. The physical mode of action of NBTXR3 makes it applicable across solid tumors.
NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I trial regarding local control. In the United States, the Company has started the regulatory process to commence a phase III clinical trial in locally advanced head and neck cancers.
Nanobiotix is also running an Immuno-Oncology development program. The Company has launched a Phase I clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 checkpoint inhibitors in locoregional recurrent (LRR) or recurrent and metastatic (R/M) HNSCC amenable to re-irradiation of the HN and lung or liver metastases (mets) from any primary cancer eligible for anti-PD-1 therapy.
Other ongoing NBTXR3 trials are treating patients with hepatocellular carcinoma (HCC) or liver metastases, locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and pancreatic cancer. The Company has a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center (initially expected to support 9 new clinical trials in the United States) to evaluate NBTXR3 across several cancer types.
About NANOBIOTIX: http://www.nanobiotix.com
Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.
The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.
Nanobiotixs first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.
Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.
This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix approved by the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.20-010 on May 12, 2020 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200529005528/en/
Nanobiotix Communications Department Brandon Owens +1 (617) email@example.com
Investor Relations Department Ricky Bhajun +33 (0)1 79 97 29 firstname.lastname@example.org
Media Relations France TBWA Corporate Pauline Richaud + 33 (0) 437 47 36 42Pauline.email@example.com
US RooneyPartners Marion Janic +1 (212) firstname.lastname@example.org
Impact of Covid-19 on Nanorobots Market Current Scenario, Bruker, Jeol, Thermo Fisher, Ginkgo Bioworks, Oxford Instruments, etc. – 3rd Watch News
The COVID-19 pandemic has disrupted lives and is challenging the business landscape globally. Pre and Post COVID-19 market outlook is covered in this report. This is the most recentreport, covering thecurrent economic situation after theCOVID-19outbreak.
The report contains a thorough summary of Nanorobots market that includes several well-known organizations, key market players who are leading in terms of sales, variable market change, revenue, end-user demands, conformity through trustworthy services, restricted elements, products and other processes. Technical advancements, surplus capacity in developing markets, market bifurcation, globalization, regulations and environmental guidelines, production and packaging are some trends that are explained in the marketreport.The report also displays the regional properties of the market history of every product type, technology, and volume during the forecast period. Apart from the mentioned information, the growth rate of the Global Nanorobots Market is also explained throughout a couple of years. Moreover, the report explains the market size and year-to-year development rate of the specific product or technology.
Click here to get the short-term and long-term impact of COVID-19 on this Market:https://www.reportsmonitor.com/request_sample/924511
TheMajor Manufacturers Covered in this Report:Bruker, Jeol, Thermo Fisher, Ginkgo Bioworks, Oxford Instruments, Ev Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik, Xidex, Synthace, Park Systems, Smaract, Nanonics Imaging, Novascan Technologies, Angstrom Advanced, Hummingbird Scientific, Nt-Mdt Spectrum Instruments, Witec
Type SegmentationNanomanipulatorBio-NanoroboticsMagnetically GuidedBacteria-Based
Speak to our industry expert and avail discount on Market [emailprotected]https://www.reportsmonitor.com/check_discount/924511
Important Features of the report:
Explore Full Report with Detailed TOC, Charts, Tables and [emailprotected]https://www.reportsmonitor.com/report/924511/Nanorobots-Market
To conclude, the Nanorobots Industry report mentions the key geographies, market landscapes alongside the product price, revenue, volume, production, supply, demand, market growth rate, and forecast, etc. This report also provides SWOT analysis, investment feasibility analysis, and investment return analysis.
Contact Us:Jay MatthewsDirect: +1 513 549 5911 (U.S.), +44 203 318 2846 (U.K.)Email: [emailprotected]
Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and… – Azizsalon News
Nanomedicine Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026.
Nanomedicine Market Drivers and Restrains:Nanomedicine is an application of nanotechnology, which are used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine usages nanoscale manipulation of materials to improve medicine delivery. Therefore, nanomedicine has facilitated the treatment against various diseases. The nanomedicine market includes products that are nanoformulations of the existing drugs and new drugs or are nanobiomaterials. The research and development of new devices as well as the diagnostics will become, more effective, enabling faster response and the ability to treat new diseases are likely to boost the market growth.
REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/39223
The nanomedicine markets are driven by factors such as developing new technologies for drug delivery, increase acceptance of nanomedicine across varied applications, rise in government support and funding, the growing need for therapies that have fewer side effects and cost-effective. However, long approval process and risks associated with nanomedicine (environmental impacts) are hampering the market growth at the global level. An increase in the out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are likely to create lucrative opportunities in the nanomedicine market.
The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.
Nanomedicine Market Segmentation Analysis:Based on the application, the nanomedicine market has been segmented into cardiovascular, neurology, anti-infective, anti-inflammatory, and oncology. The oncology segment held the dominant market share in 2018 and is projected to maintain its leading position throughout the forecast period owing to the rising availability of patient information and technological advancements. However, the cardiovascular and neurology segment is projected to grow at the highest CAGR of XX% during the forecast period due to presence of opportunities such as demand for specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration.
Nanomedicine Market Regional Analysis:Geographically, the Nanomedicine market has been segmented into North America, the Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the Nanomedicine market in 2018 due to the rising presence of patented nanomedicine products, the availability of advanced healthcare infrastructure and the rapid acceptance of nanomedicine. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period thanks to rise in number of research grants and increase in demand for prophylaxis of life-threatening diseases. Moreover, the rising investments in research and development activities for the introduction of advanced therapies and drugs are predicted to accelerate the growth of this region in the near future.
Nanomedicine Market Competitive landscapeMajor Key players operating in this market are Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc, and Johnson & Johnson. Manufacturers in the nanomedicine are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.
The objective of the report is to present a comprehensive analysis of Nanomedicine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Nanomedicine Market dynamics, structure by analyzing the market segments and project the Nanomedicine Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product portfolio, Growth strategies, and regional presence in the Nanomedicine Market make the report investors guide.
DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/39223
Scope of the Nanomedicine Market:
Nanomedicine Market by Modality:
Diagnostics TreatmentsNanomedicine Market by Diseases:
Oncological Diseases Infectious Diseases Cardiovascular Diseases Orthopedic Disorders Neurological Diseases Urological Diseases Ophthalmological Diseases Immunological DiseasesNanomedicine Market by Application:
Neurology Cardiovascular Anti-Inflammatory Anti-Infectives OncologyNanomedicine Market by Region:
Asia Pacific North America Europe Latin America Middle East AfricaNanomedicine Market Major Players:
Abbott Laboratories CombiMatrix Corporation General Electric Company Sigma-Tau Pharmaceuticals, Inc Johnson & Johnson Mallinckrodt plc. Merck & Company, Inc. Nanosphere, Inc. Pfizer, Inc. Teva Pharmaceutical Industries Ltd. Celgene Corporation UCB (Union Chimique Belge) S.A. AMAG Pharmaceuticals Nanospectra Biosciences, Inc. Arrowhead Pharmaceuticals, Inc. Leadiant Biosciences, Inc. Epeius Biotechnologies Corporation Cytimmune Sciences, Inc.
MAJOR TOC OF THE REPORT
Chapter One: Nanomedicine Market Overview
Chapter Two: Manufacturers Profiles
Chapter Three: Global Nanomedicine Market Competition, by Players
Chapter Four: Global Nanomedicine Market Size by Regions
Chapter Five: North America Nanomedicine Revenue by Countries
Chapter Six: Europe Nanomedicine Revenue by Countries
Chapter Seven: Asia-Pacific Nanomedicine Revenue by Countries
Chapter Eight: South America Nanomedicine Revenue by Countries
Chapter Nine: Middle East and Africa Revenue Nanomedicine by Countries
Chapter Ten: Global Nanomedicine Market Segment by Type
Chapter Eleven: Global Nanomedicine Market Segment by Application
Chapter Twelve: Global Nanomedicine Market Size Forecast (2019-2026)
Browse Full Report with Facts and Figures of Nanomedicine Market Report at: https://www.maximizemarketresearch.com/market-report/nanomedicine-market/39223/
Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
Name: Vikas Godage
Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.
Contact: +919607065656/ +919607195908